Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed this Form 8-K on January 14, 2015, reporting a material event that occurred on January 8, 2015. The filing details the entry into a Second Amended and Restated Strategic Collaboration and License Agreement with Isis Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a strategic agreement.
Material Changes and Agreement Details
The primary material change is the execution of the "2015 Agreement" with Isis Pharmaceuticals, which includes:
- Exclusive Target Cross-Licenses:
- Isis granted Alnylam an exclusive, low single-digit royalty-bearing license for oligonucleotide therapeutics targeting antithrombin and aminolevulinic acid synthase-1.
- Alnylam granted Isis an exclusive, low single-digit royalty-bearing license for oligonucleotide therapeutics targeting Factor XI and apolipoprotein (a).
- Extension of Non-Exclusive Technology Cross-License:
- The existing non-exclusive cross-license, originally from 2004 and amended in 2009, is extended through April 2019.
- Isis grants Alnylam a non-exclusive license to new RNA interference (RNAi) platform technology arising from May 2014 through April 2019.
- Alnylam grants Isis a non-exclusive license to new single-stranded antisense platform technology arising from May 2014 through April 2019.
- These licenses cover chemistry, motif, and mechanism patents but exclude formulations, manufacturing, and specific targets.
- Term and Termination:
- The agreement generally ends upon the expiration of the last-to-expire licensed patent.
- Either party may terminate on 90 days' written notice for material breach, provided the breach is not cured.
- Termination does not affect licenses necessary to develop or sell products that have reached investigational new drug-enabling studies.
- Termination is permitted in the event of specified bankruptcy events by the other party.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or a discussion of general business risks. The primary contingency noted is the potential for termination due to material breach or bankruptcy events.
Key Facts for Investor Verification
- Verify the specific royalty rates described as "low single-digit" in the exclusive licenses.
- Confirm the development status of the four targeted programs (antithrombin, aminolevulinic acid synthase-1, Factor XI, and apolipoprotein (a)) to assess the commercial value of the cross-licenses.
- Review the scope of the "new platform technology" licensed under the non-exclusive extension to understand the competitive landscape for RNAi and antisense therapeutics.
- Monitor future filings for any financial impact or milestone payments resulting from this agreement.